Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

NCT05731752 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: HX009

Sponsor

Hangzhou Hanx Biopharmaceuticals, Ltd.